These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25825160)

  • 1. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.
    Tataranni T; Agriesti F; Mazzoccoli C; Ruggieri V; Scrima R; Laurenzana I; D'Auria F; Falzetti F; Di Ianni M; Musto P; Capitanio N; Piccoli C
    Br J Haematol; 2015 Jul; 170(2):236-46. PubMed ID: 25825160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.
    Tataranni T; Mazzoccoli C; Agriesti F; De Luca L; Laurenzana I; Simeon V; Ruggieri V; Pacelli C; Della Sala G; Musto P; Capitanio N; Piccoli C
    Stem Cell Res Ther; 2019 Jun; 10(1):171. PubMed ID: 31196186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.
    Pullarkat V; Sehgal A; Li L; Meng Z; Lin A; Forman S; Bhatia R
    Leuk Res; 2012 Aug; 36(8):966-73. PubMed ID: 22502920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.
    Banerjee A; Mifsud NA; Bird R; Forsyth C; Szer J; Tam C; Kellner S; Grigg A; Motum P; Bentley M; Opat S; Grigoriadis G
    Br J Haematol; 2015 Feb; 168(4):576-82. PubMed ID: 25271366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
    Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
    Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.
    Shen JC; Zhang YC; Zhao MF
    Braz J Med Biol Res; 2017 Oct; 50(12):e6087. PubMed ID: 29069221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
    Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
    Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
    Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X
    Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
    Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
    Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.
    Brewer C; Otto-Duessel M; Lykkesfeldt J; Nick H; Wood JC
    Exp Hematol; 2012 Oct; 40(10):820-7. PubMed ID: 22713799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
    Messa E; Carturan S; Maffè C; Pautasso M; Bracco E; Roetto A; Messa F; Arruga F; Defilippi I; Rosso V; Zanone C; Rotolo A; Greco E; Pellegrino RM; Alberti D; Saglio G; Cilloni D
    Haematologica; 2010 Aug; 95(8):1308-16. PubMed ID: 20534700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
    Kim JL; Lee DH; Na YJ; Kim BR; Jeong YA; Lee SI; Kang S; Joung SY; Lee SY; Oh SC; Min BW
    Tumour Biol; 2016 Jul; 37(7):9709-19. PubMed ID: 26803514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
    Salehi S; Saljooghi ASh; Shiri A
    Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
    Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
    Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
    Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
    BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron chelators induce autophagic cell death in multiple myeloma cells.
    Pullarkat V; Meng Z; Donohue C; Yamamoto VN; Tomassetti S; Bhatia R; Krishnan A; Forman SJ; Synold TW
    Leuk Res; 2014 Aug; 38(8):988-96. PubMed ID: 24998390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
    Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
    Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT; Temraz S; Cappellini MD
    Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
    Guariglia R; Martorelli MC; Villani O; Pietrantuono G; Mansueto G; D'Auria F; Grieco V; Bianchino G; Lerose R; Bochicchio GB; Musto P
    Leuk Res; 2011 May; 35(5):566-70. PubMed ID: 21185078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.